AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21223542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 19336812 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial bursectomy alone
Number of subjects: 57
Study 19336812 — intervention group
Group type: COMPARATOR
Intervention: Debridement of the subacromial bursa followed by acromioplasty
Number of subjects: 57
Study 16987766 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation
Number of subjects: 20
Study 16987766 — intervention group
Group type: COMPARATOR
Intervention: Mucous membrane grafting
Number of subjects: 20
Study 12700707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 30
Study 12700707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11197651 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF therapy (group 1)
Number of subjects: 137
Study 11197651 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (group 2)
Number of subjects: 137
Study 11197651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of laser with EHF‐puncture (group 3)
Number of subjects: 137
Study 11197651 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (group 4, control)
Number of subjects: 137
Study 9120155 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mmol of magnesium/12 mmol of potassium-DL-hydrogenaspartate daily
Number of subjects: 232
Study 9120155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 12959290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8
Study 12959290 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating (standard 3100 kJ cold meal)
Number of subjects: 8
Study 12959290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3475429 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (A, 55 subjects)
Number of subjects: 212
Study 3475429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium diet (B, 52 subjects receiving greater than 100 mmol K+/day)
Number of subjects: 212
Study 3475429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-sodium diet (C, 52 subjects receiving 50‐75 mmol Na+/day)
Number of subjects: 212
Study 3475429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium and low-sodium diet (D, 53 subjects receiving same Na+ and K+ as groups B and C)
Number of subjects: 212
Study 30106214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceased pacing (CeP)
Number of subjects: 21
Study 30106214 — intervention group
Group type: COMPARATOR
Intervention: Continued pacing (CoP)
Number of subjects: 21
Study 27171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 8 to 10 cm H2O
Number of subjects: 33
Study 27171827 — intervention group
Group type: COMPARATOR
Intervention: Atmospheric pressure (Control)
Number of subjects: 33
Study 25590292 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous exercise and psychotherapy (STEP) group (n = 26)
Number of subjects: 78
Study 25590292 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy (TALK group) (n = 26)
Number of subjects: 78
Study 25590292 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control group) (n = 26)
Number of subjects: 78
Study 22380920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Enablement Protocol (VEP)
Number of subjects: 160
Study 20381924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by a peer (patient on antiretroviral therapy)
Number of subjects: 240
Study 20381924 — intervention group
Group type: COMPARATOR
Intervention: Intervention by a health professional
Number of subjects: 240
Study 20381924 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving a drug combination including a protease inhibitor
Number of subjects: 240
Study 20381924 — intervention group
Group type: COMPARATOR
Intervention: Patients with psychological distress
Number of subjects: 240
Study 20381924 — intervention group
Group type: COMPARATOR
Intervention: Patients with a higher score on the physical quality of life index
Number of subjects: 240
Study 18753118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir capsules (once or twice daily) with tenofovir DF and emtricitabine (both once daily) for 96 weeks
Number of subjects: 190
Study 16120556 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with spastic diplegia
Number of subjects: 22
Study 16120556 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 12192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective cyclo-oxygenase inhibitors (COX-II)
Number of subjects: 0
Study 12192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs
Number of subjects: 0
Study 12192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine, diacerein, and hyaluronan
Number of subjects: 0
Study 9989555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline plus interpersonal psychotherapy (N = 16)
Number of subjects: 80
Study 9989555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline alone in a medication clinic (N = 25)
Number of subjects: 80
Study 9989555 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus interpersonal psychotherapy (N = 17)
Number of subjects: 80
Study 9989555 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone in a medication clinic (N = 22)
Number of subjects: 80
Study 8578012 — intervention group
Group type: EXPERIMENTAL
Intervention: External resistive loads (15 mm, 10 mm, 8 mm, 6 mm orifices)
Number of subjects: 14
Study 8578012 — intervention group
Group type: EXPERIMENTAL
Intervention: External resistive loads (10 mm and 8 mm orifices) during steady-state bicycle exercise
Number of subjects: 14
Study 8578012 — intervention group
Group type: EXPERIMENTAL
Intervention: External resistive loads (6 mm orifice)
Number of subjects: 14
Study 2180462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 120
Study 2180462 — intervention group
Group type: COMPARATOR
Intervention: Cephamandole
Number of subjects: 120
Study 7373080 — intervention group
Group type: COMPARATOR
Intervention: Inactivated B/Hong Kong virus vaccine
Number of subjects: 0
Study 7373080 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile respiratory illness monitoring
Number of subjects: 0
Study 7373080 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza B virus infection
Number of subjects: 0
Study 7373080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemagglutination‐inhibiting antibody response
Number of subjects: 0
Study 31754078 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM)
Number of subjects: 40
Study 31754078 — intervention group
Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 40
Study 29910047 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil, a phosphodiesterase type 5 inhibitor, dosage and duration not specified
Number of subjects: 0
Study 29910047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27351159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative nerve root monitoring using the INS‐1‐System (NuVasive, San Diego USA)
Number of subjects: 22
Study 27351159 — intervention group
Group type: COMPARATOR
Intervention: Control group (screws inserted without additional pedicle monitoring)
Number of subjects: 22
Study 22465123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 78
Study 22465123 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 22449253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily
Number of subjects: 39
Study 22449253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22449253 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 39
Study 20718169 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (n=51)
Number of subjects: 100
Study 20718169 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed weaning (n=49)
Number of subjects: 100
Study 17921381 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin A administered with BCG vaccine at birth
Number of subjects: 614
Study 17921381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 614
Study 16140232 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of airflow obstruction (assessed by FEV(1)% predicted)
Number of subjects: 2116
Study 16140232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior hospitalisation and home oxygen use
Number of subjects: 2116
Study 16140232 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of comorbid conditions and symptoms of dyspnoea
Number of subjects: 2116
Study 12401247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ban on coal sales (intervention)
Number of subjects: 0
Study 10327697 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch technique
Number of subjects: 0
Study 10327697 — intervention group
Group type: COMPARATOR
Intervention: Colposuspension and support techniques
Number of subjects: 0
Study 10327697 — intervention group
Group type: COMPARATOR
Intervention: Sling techniques
Number of subjects: 0
Study 8712116 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg intravenously in 2 minutes)
Number of subjects: 29
Study 8712116 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (10 mg/kg intravenously at an injection speed of 100 mg/min)
Number of subjects: 29
Study 8712116 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 29
Study 8712116 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 29
Study 1876376 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable staples
Number of subjects: 60
Study 1876376 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 60
Study 6626854 — intervention group
Group type: EXPERIMENTAL
Intervention: Faded phobic cine-film exposure
Number of subjects: 32
Study 6626854 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal phobic cine-film exposure
Number of subjects: 32
Study 6626854 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal phobic cine-film exposure
Number of subjects: 32
Study 6626854 — intervention group
Group type: COMPARATOR
Intervention: Control group (potter working on wheel)
Number of subjects: 32
Study 31847979 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended education program for 4 weeks
Number of subjects: 60
Study 31847979 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face education (Control)
Number of subjects: 60
Study 28403569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 120
Study 28403569 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 28403569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 26415612 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual neurofeedback training (12 sessions over 6 weeks)
Number of subjects: 25
Study 26415612 — intervention group
Group type: COMPARATOR
Intervention: No additional NF intervention (control group)
Number of subjects: 25
Study 25790416 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite multiple-component intervention addressing diet and physical activity
Number of subjects: 3799
Study 25790416 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3799
Study 25790416 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in differences (DID)
Number of subjects: 3799
Study 22502833 — intervention group
Group type: EXPERIMENTAL
Intervention: home-based virtual cycling training (hVCT)
Number of subjects: 28
Study 22502833 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 28
Study 20428608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate (160 mg) with alcohol
Number of subjects: 15
Study 20428608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate (160 mg) alone
Number of subjects: 15
Study 20428608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18803991 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/100 microg BID
Number of subjects: 548
Study 18803991 — intervention group
Group type: COMPARATOR
Intervention: MON 5-mg tablet QD
Number of subjects: 548
Study 18803991 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 548
Study 18803991 — intervention group
Group type: COMPARATOR
Intervention: MON
Number of subjects: 548
Study 16061734 — intervention group
Group type: EXPERIMENTAL
Intervention: CONJ‐hBNP
Number of subjects: 0
Study 16061734 — intervention group
Group type: COMPARATOR
Intervention: native hBNP
Number of subjects: 0
Study 11799078 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (1 g/min; total 30 g)
Number of subjects: 11
Study 11799078 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine infusion (control)
Number of subjects: 11
Study 11799078 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine infusion
Number of subjects: 11
Study 11799078 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 11
Study 10818895 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive hydro‐cellular dressing
Number of subjects: 50
Study 10818895 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze dressing
Number of subjects: 50
Study 8750409 — intervention group
Group type: EXPERIMENTAL
Intervention: Three alternative models of patient counseling
Number of subjects: 0
Study 8750409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1827283 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 80
Study 1827283 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 80
Study 6662724 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial dosage of oral aromatic retinoid (75 mg leads to 50 leads to 35 mg; approximately 1 mg/kg/d leads to approximately 0.5 mg/kg/d)
Number of subjects: 70
Study 6662724 — intervention group
Group type: COMPARATOR
Intervention: Low initial dosage of oral aromatic retinoid (35 mg leads to 50 mg/d leads to 75 mg/d; approximately 0.5 mg/kg/d leads to approximately 1.0 mg/kg/d)
Number of subjects: 70
Study 6662724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate doses of oral aromatic retinoid (35-60 mg/d; approximately 0.4-0.8 mg/kg/d)
Number of subjects: 70
Study 6662724 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial dosage of retinoid
Number of subjects: 70
Study 6662724 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical side effects (cheilitis, desquamation, hair loss)
Number of subjects: 70
Study 6662724 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevations of serum triglycerides
Number of subjects: 70
Study 6662724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair loss in females
Number of subjects: 70
Study 30539282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with intravesical chemotherapy (Group A, n=68)
Number of subjects: 203
Study 30539282 — intervention group
Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (Group B, n=135)
Number of subjects: 203
Study 28122931 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D supplements every 2 weeks for 6 months
Number of subjects: 60
Study 28122931 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 6 months
Number of subjects: 60
Study 25689146 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056 (25-150 mg, twice-daily)
Number of subjects: 42
Study 25689146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25022106 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with auricular point sticking
Number of subjects: 90
Study 25022106 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture
Number of subjects: 90
Study 25022106 — intervention group
Group type: COMPARATOR
Intervention: Western medication (aniracetam tablets, 0.2 g twice a day)
Number of subjects: 90
Study 21986389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol), 2000 IU/day
Number of subjects: 20000
Study 21986389 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acid (Omacor fish oil, EPA+DHA), 1g/day
Number of subjects: 20000
Study 21986389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20000
Study 19487506 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of medial collateral ligament (Group I, n = 23)
Number of subjects: 47
Study 19487506 — intervention group
Group type: COMPARATOR
Intervention: Anterior cruciate ligament reconstruction only (Group II, n = 24)
Number of subjects: 47
Study 17580264 — intervention group
Group type: EXPERIMENTAL
Intervention: (T)BU/CY
Number of subjects: 222
Study 17580264 — intervention group
Group type: COMPARATOR
Intervention: CY/TBI
Number of subjects: 222
Study 17893453 — intervention group
Group type: EXPERIMENTAL
Intervention: Profound hemodilution (hematocrit on cardiopulmonary bypass of 15‐18%)
Number of subjects: 108
Study 17893453 — intervention group
Group type: COMPARATOR
Intervention: Moderate hemodilution (hematocrit on cardiopulmonary bypass >or=27%)
Number of subjects: 108
Study 15575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal silver dressing
Number of subjects: 125
Study 15575569 — intervention group
Group type: COMPARATOR
Intervention: Cleansing and debridement (control)
Number of subjects: 125
Study 10856489 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine gel
Number of subjects: 500
Study 10856489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no anesthesia)
Number of subjects: 500
Study 9188228 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based periodontal therapy
Number of subjects: 0
Study 9188228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 0
Study 9188228 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy
Number of subjects: 0
Study 9188228 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implants
Number of subjects: 0
Study 8252492 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and flutamide
Number of subjects: 0
Study 8252492 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 0
Study 3548985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 to 750 mg daily, increased to a maximum of 1 gm daily during the open-label phase)
Number of subjects: 0
Study 3548985 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (2.6 to 3.9 gm daily)
Number of subjects: 0
Study 31265915 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device or smartphone application to track physical activity data
Number of subjects: 0
Study 31265915 — intervention group
Group type: COMPARATOR
Intervention: Standard modelling approaches
Number of subjects: 0
Study 28479526 — intervention group
Group type: EXPERIMENTAL
Intervention: Superion device
Number of subjects: 122
Study 26264837 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized nicotine
Number of subjects: 20
Study 26264837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22617142 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported FFQ for EPA
Number of subjects: 78
Study 22617142 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported FFQ for DHA
Number of subjects: 78
Study 22617142 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported FFQ for sum of n-3 PUFA
Number of subjects: 78
Study 22617142 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte levels of EPA
Number of subjects: 78
Study 22617142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranked thirds of dietary intake, blood and dermis
Number of subjects: 78
Study 21791491 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockade (valsartan 320 mg/day) plus regular sodium diet (200 mmol Na(+)/day)
Number of subjects: 52
Study 21791491 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockade (valsartan 320 mg/day) plus low sodium diet (50 mmol Na(+)/day)
Number of subjects: 52
Study 21791491 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibition (lisinopril 40 mg/day) plus regular sodium diet (200 mmol Na(+)/day)
Number of subjects: 52
Study 21791491 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition (lisinopril 40 mg/day) plus low sodium diet (50 mmol Na(+)/day)
Number of subjects: 52
Study 21791491 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition (lisinopril 40 mg/day) plus angiotensin receptor blockade (valsartan 320 mg/day)
Number of subjects: 52
Study 19422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Live modelling with mother as model
Number of subjects: 155
Study 19422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Live modelling with father as model
Number of subjects: 155
Study 19422751 — intervention group
Group type: COMPARATOR
Intervention: Tell-show-do method
Number of subjects: 155
Study 16859866 — intervention group
Group type: EXPERIMENTAL
Intervention: Information brochure provided at least 1 day before the gastroscopy
Number of subjects: 95
Study 16859866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brochure)
Number of subjects: 95
Study 15745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Essay test format
Number of subjects: 67
Study 15745073 — intervention group
Group type: COMPARATOR
Intervention: Fill-in test format
Number of subjects: 67
Study 15745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test formats
Number of subjects: 67
Study 11552907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 26
Study 11552907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 420 mg
Number of subjects: 26
Study 11552907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus calcium carbonate
Number of subjects: 26
Study 11552907 — intervention group
Group type: COMPARATOR
Intervention: Antacid alone
Number of subjects: 26
Study 11552907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus antacid
Number of subjects: 26